番茄社区app

The FDA to include treatment of adults with moderately to severely active Crohn's disease, drugmaker Eli Lilly announced; the first-in-class interleukin-23 antagonist was previously approved for ulcerative colitis.

In Crohn's disease patients, was associated with better clinical outcomes and decreases in markers of inflammation, a prospective cohort study found. (Gastroenterology)

Physiological data captured passively from wearable devices like Fitbits or Apple Watches . (Gastroenterology)

Combing 5-aminosalicylic acid with ustekinumab (Stelara) did not appear to provide a clinical benefit in IBD, suggested. (Inflammatory Bowel Diseases)

Meanwhile, adalimumab (Humira) could be a safe option for very early-onset IBD, . (Inflammatory Bowel Diseases)

Authors of a narrative review in Clinical Gastroenterology and Hepatology examined various lifestyle approaches and pharmacologics for reducing the .

The investigational pan-peroxisome proliferator-activated receptor (PPAR) agonist in a phase II study of MASLD patients with diabetes. (Journal of Hepatology)

Frequency of polyp diagnoses among family members was linked with , especially early-onset cancers. (Gastroenterology)

Which -- i.e., fecal immunochemical testing, stool DNA tests, or blood-based assays -- are most cost-effective in community clinics? (JAMA Network Open)

A clinical practice update from the American Gastroenterological Association weighed in on . (Clinical Gastroenterology and Hepatology)

In a placebo-controlled phase II trial, in patients with cirrhosis appeared safe and was associated with lower recurrence rates. (Journal of Hepatology)

reduced the risk of gastric cancer and death from gastric cancer, a meta-analysis of 11 randomized trials and 13 observational studies found. (Gastroenterology)

Comment